• Clinical Insights: September 14, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval No new update. New Formulation Approval No new update. New Indication/Dosage Approval No new update. New/Updated Drug Shortage September 10, 2021 Atropine Sulfate Injection (Currently in Shortage) Bacitracin… Read more »

  • Clinical Insights: September 8, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Trudhesa™ (dihydroergotamine mesylate) Nasal Spray – New Drug Approval – September 3, 2021 –  Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from… Read more »

  • Clinical Insights: August 31, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Tibsovo® (ivosidenib) – New Drug Approval – August 25, 2021 – The Food and Drug Administration approved ivosidenib (Tibsovo®, Servier Pharmaceuticals LLC) for adult patients with previously treated,… Read more »

  • Clinical Insights: August 24, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Comirnaty™ (Pfizer-BioNTech COVID-19 Vaccine) – New Vaccine Approval – August 23, 2021 – The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been… Read more »

  • Clinical Insights: August 17, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Welireg™ (belzutifan) Tablets – New Drug Approval – August 13, 2021 – The Food and Drug Administration approved belzutifan (Welireg™, Merck), a hypoxia-inducible factor inhibitor for adult patients with… Read more »

  • Clinical Insights: August 10, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Nexviazyme® (avalglucosidase alfa-ngpt) Intravenous Infusion – New Orphan Drug Approval – August 6, 2021 – The U.S. Food and Drug Administration approved Genzyme’s Nexviazyme® (avalglucosidase alfa-ngpt) for intravenous… Read more »

  • Clinical Insights: August 3, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Twyneo® (tretinoin and benzoyl peroxide) Cream – New Drug Approval – July 27, 2021 – Sol-Gel Technologies, Ltd., a dermatology company focused on identifying, developing and commercializing branded and… Read more »

  • Clinical Insights: July 27, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Bylvay™ (odevixibat) Capsules – New Drug Approval – July 20, 2021 – Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, announced the U.S. Food… Read more »

  • Clinical Insights: July 20, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Rezurock™ (belumosudil) Tablets – New Drug Approval – July 16, 2021 – The Food and Drug Administration approved belumosudil (Rezurock™, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and… Read more »

  • Clinical Insights: July 13, 2021

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Padcev™ (enfortumab vedotin-ejfv) – New Drug Approval – July 9, 2021 – The Food and Drug Administration approved enfortumab vedotin-ejfv (Padcev™, Astellas Pharma US, Inc.), a Nectin-4-directed antibody… Read more »